Overview

The majority of Australia’s active pharmaceutical ingredients, medical devices and finished drug products are imported. These are typically priced in US dollars, euros or Swiss francs. Revenue is meanwhile earned predominantly in AUD through PBS (Pharmaceuticals Benefits Scheme) listings, hospital procurement and retail pharmacy.

The sector also carries unique commercial risks: high R&D costs, long regulatory approval timelines, patent cliffs and government pricing interventions (including PBS price reductions) can all compress margins. In that environment, adding unmanaged currency risk on top of existing industry pressures represents a huge vulnerability.

Smart Currency Business works with Australian pharmaceutical and biomedical companies to design treasury management solutions that protect import costs, support cashflow planning and simplify the complex risk landscape.

Key challenges

Import cost exposure: Active ingredients, finished products and medical devices sourced from the US, Europe and Switzerland are priced in foreign currencies. A weakening AUD inflates landed costs and compresses margins on products where pricing is often fixed by PBS or contract.

Long revenue timelines: Pharmaceutical companies may incur foreign currency R&D and regulatory costs years before generating Australian revenue. This creates long-dated exposure that requires careful planning.

Regulatory pricing pressure: PBS pricing reviews and government interventions can reduce the AUD revenue side of the equation. When your selling price is constrained, controlling your input costs (including FX costs) becomes even more critical.

Patent and exclusivity risk: When product patents expire and generics enter the market, revenue can drop sharply. A hedging solution needs to accommodate significant volume uncertainty in these transition periods.

How we help

We work with your procurement and finance teams to map import costs by currency, supplier and settlement date, then design a forward programme that locks in AUD costs at the point of order — protecting your margins even when PBS or contract pricing constrains your revenue.

For companies with long-dated R&D commitments in foreign currencies, we structure hedging over extended horizons, providing budget certainty for clinical trial costs and regulatory submissions.